CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Ex vivo lung perfusion with Steen Solution™drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01190059
NCT01190059Phase 1Completed
CompareCT.gov

Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation

XVIVO Perfusion·interventional·Posted Aug 27, 2010·Updated Apr 4, 2025

In Brief

A Phase 1 clinical trial evaluating Ex vivo lung perfusion with Steen Solution™ for Lung Transplantation. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The use of ex vivo lung perfusion (EVLP) will allow for a secondary evaluation technique for donor lungs that fail to meet standard acceptability criteria. This advanced assessment might lead to increased utilization rates of donor lungs and improved outcomes after lung transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Transplantation
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 27, 2010
Enrollment StartAug 1, 2008
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.8 years ago

Interventions

Ex vivo lung perfusion with Steen Solution™drug

The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.